Navigation Links
Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
Date:12/11/2007

ATLANTA, Dec. 11 /PRNewswire-USNewswire/ -- The Arthritis Foundation, the leading health organization addressing the needs of 46 million Americans living with arthritis, today announced that Amgen and Wyeth Pharmaceuticals, co-marketers of Enbrel (R) (etanercept), will be the national presenting sponsor of the 2008 Arthritis Walk (R).

"The Arthritis Foundation hosts hundreds of Arthritis Walk events nationwide to raise funds to prevent, control and cure arthritis, the nation's most common cause of disability," said Becky Burkett, chief development officer of the Arthritis Foundation. "This generous sponsorship from Amgen and Wyeth will provide a unique opportunity to generate awareness about arthritis while raising funds that are critical to helping find a cure for this debilitating condition."

As part of the sponsorship, the Arthritis Foundation will launch a new program in which the organization will reach out to rheumatologists and members of the Association of Rheumatology Health Professionals in an effort to help boost attendance and awareness of the Arthritis Walk by encouraging doctors and their patients to walk together.

"We're excited to have the opportunity to support a program that benefits the entire arthritis community," said Jeffrey M. Melin, M.D., M.P.H., senior director, Musculoskeletal and Inflammatory Diseases, Wyeth Research. "We encourage people with arthritis to join the Arthritis Walk together with their doctor, as well as their friends and family, and to take an active role in improving their own health, while raising awareness and funding for arthritis research."

"Arthritis can pose challenges to physical activity, but it does not have to mean the end of an active and healthy lifestyle," said Scott Baumgartner, M.D., director, Global Development, Inflammation Therapeutic Area, Amgen. "We hope that together with the Arthritis Foundation we can empower and motivate people with rheumatoid arthritis to consult with their rheumatologist and start or restart an appropriate fitness program."

Arthritis Walk events, which take place nationwide, kick off National Arthritis Month in May. Walking as little as 30 minutes -- even 10 minutes three times a day -- can be beneficial for everyone and may ease joint pain and improve mobility. For people with arthritis, experts believe that light exercise such as walking may decrease fatigue, strengthen bones and muscles, and enhance flexibility and stamina. To sign up for an Arthritis Walk event, visit http://www.arthritis.org.

While often referred to as if it were a single disease, arthritis is actually an umbrella term used for a group of more than 100 medical conditions that collectively affect the joints of nearly 46 million adults and 300,000 children in America alone. Osteoarthritis, the most common form of arthritis, is most prevalent in people over 60 years of age, while rheumatoid arthritis appears primarily in women in their young- to mid-adult years. Juvenile rheumatoid arthritis is the most common form of arthritis in children.

About the Arthritis Foundation

The Arthritis Foundation is the leading health organization addressing the needs of some 46 million Americans living with arthritis, the nation's most common cause of disability. Founded in 1948, with headquarters in Atlanta, the Arthritis Foundation has multiple service points located throughout the country.

The Arthritis Foundation is the largest private, not-for-profit contributor to arthritis research in the world, funding more than $380 million in research grants since 1948. The foundation helps individuals take control of arthritis by providing public health education; pursuing public policy and legislation; and conducting evidence-based programs to improve the quality of life for those living with arthritis. Information is available 24 hours a day, seven days a week at 1-800-283-7800 or http://www.arthritis.org.

About Amgen and Wyeth

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, market ENBREL in North America. Wyeth markets ENBREL outside of North America. Immunex Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL, which may be used to treat rheumatoid arthritis, junior rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis. Additional information about ENBREL, including the full U.S. Prescribing Information, can be found on the Web site sponsored by the companies at http://www.enbrel.com or by calling, in the U.S., toll free 888-4ENBREL (888-436-2735).

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about Amgen's pioneering science and vital medicines, visit http://www.amgen.com.

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health. To learn more, visit http://www.wyeth.com.


'/>"/>
SOURCE Arthritis Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
5. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
6. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , May 31, 2016 , ... demand for its Patient Status Engine wireless patient monitoring platform, ... , Germany , Scotland ... The company,s 2 nd generation system, launched earlier this year, ... the world , , This new technology ...
(Date:5/30/2016)... May 30, 2016 ... "Healthcare Biometrics Market by Technology (Single-factor (Fingerprint, ... Multimodal), Application (Workforce Management), End User (Hospitals, ... published by MarketsandMarkets, the market is projected ... from USD 1,182.6 Million by 2016, at ...
(Date:5/30/2016)... 2016 - DCGI grants limited approval to ... disease - Stempeucel® becomes 5th off-the-shelf Stem cell product ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is ... and Globally - Prevalence of Buerger,s Disease is estimated ... per 10,000 persons in the European Community & USA ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Sunny Isles Beach is in the ... flooding, or loss of utility services. The time for planning is now, before a ... have a plan in place. Families should follow the recommendations of the Miami-Dade County ...
(Date:5/31/2016)... , ... May 31, 2016 , ... According to recent ... States, and more than 100,000 physical therapy clinics. Each physical therapy professional and ... of clients. At the same time, staying afloat in a competitive industry is also ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... Pardoe, FDAI, DAHC, CDC, has joined the Fire Door Solutions’ team. Keith ... and fire door and frame in-field re-labeling. He will be instrumental in ...
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis C ... event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise awareness ... liver cancer. , Foundation leaders and the citywide coalition they created, Hep B United ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical Center ... information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and in ... organizations in the exchange. SJMC’s membership in the health information exchange underscores the ...
Breaking Medicine News(10 mins):